Exscientia (NASDAQ:EXAI) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Exscientia plc (NASDAQ:EXAI) saw unusually-high trading volume on Monday . Approximately 972,132 shares traded hands during trading, an increase of 50% from the previous session’s volume of 649,989 shares.The stock last traded at $4.59 and had previously closed at $4.69.

Analyst Ratings Changes

A number of equities analysts have issued reports on EXAI shares. TD Cowen reiterated a “hold” rating on shares of Exscientia in a report on Friday, August 9th. Barclays reissued an “equal weight” rating and set a $5.00 price target on shares of Exscientia in a research report on Tuesday, August 13th.

Exscientia Price Performance

The company has a current ratio of 4.54, a quick ratio of 5.93 and a debt-to-equity ratio of 0.06. The firm has a market cap of $595.72 million, a price-to-earnings ratio of -3.11 and a beta of 0.83. The business’s 50-day simple moving average is $5.04 and its two-hundred day simple moving average is $5.15.

Exscientia (NASDAQ:EXAI) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.05). Exscientia had a negative net margin of 882.09% and a negative return on equity of 49.10%. The company had revenue of $5.60 million during the quarter. As a group, research analysts expect that Exscientia plc will post -1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Exscientia

Several hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd bought a new position in shares of Exscientia during the third quarter valued at approximately $82,000. Jane Street Group LLC increased its holdings in Exscientia by 601.7% during the third quarter. Jane Street Group LLC now owns 290,154 shares of the company’s stock valued at $1,416,000 after buying an additional 248,805 shares during the last quarter. Olympiad Research LP bought a new position in shares of Exscientia in the third quarter worth approximately $448,000. China Universal Asset Management Co. Ltd. grew its holdings in Exscientia by 66.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company’s stock valued at $47,000 after buying an additional 3,821 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new position in shares of Exscientia during the 3rd quarter valued at approximately $77,000. 41.58% of the stock is currently owned by institutional investors.

Exscientia Company Profile

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.